计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S413831-5mg |
5mg |
现货 ![]() |
| |
| S413831-25mg |
25mg |
期货 ![]() |
| |
| S413831-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)- | DTXSID00648729 | NCGC00379071-01 | 1093403-33-8 | s7792 | Tazarotene- Bio-X | 5-thiazolecarboxamide,4-methyl-n-(2-(3-(4-morpholinylmethyl)im |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | SRT2104 (GSK2245840) |
| 生化机理 | SRT2104 (GSK2245840) 是一种参与能量平衡调节的选择性 SIRT1 激活剂。第二阶段 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激活剂 |
| 作用机制 | NAD 依赖性去乙酰化酶 sirtuin 1 激活因子 |
| 产品介绍 |
Information SRT2104 (GSK2245840) is a selectiveSIRT1activator involved in the regulation of energy homeostasis. Phase 2. Targets SIRT1 In vitro SRT2104 reduces p65/RelA acetylation levels in C2C12 cells. In vivo In male C57BL/6J mice, SRT2104 (100 mg/kg, p.o.) extends both mean and maximal lifespan of mice fed a standard diet, and enhances motor coordination, bone mineral density, and insulin sensitivity and decreased inflammation. Short-term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy. In Male N171-82Q HD mice, SRT2104 (diet containing 0.5% SRT2104) effectively penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival. Cell Research(from reference) Cell lines:C2C12 cell line Concentrations:3\xa0μM Incubation Time:24 h |
| 纯度 | ≥98% |
| ALogP | 2.813 |
|---|---|
| HBD Count | 1 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504769966 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide |
| INCHI | 1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33) |
| InChi Key | LAMQVIQMVKWXOC-UHFFFAOYSA-N |
| Smiles | CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6 |
| Isomeric SMILES | CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6 |
| PubChem CID | 25108829 |
| 分子量 | 516.64 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 5 mg/mL warmed with 50ºC Water: bath (9.67 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 16 |
| DMSO(mM) Max Solubility | 30.96934035 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 516.600 g/mol |
| XLogP3 | 4.200 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 516.14 Da |
| 单同位素质量Monoisotopic Mass | 516.14 Da |
| 拓扑极表面积Topological Polar Surface Area | 141.000 Ų |
| 重原子数Heavy Atom Count | 36 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 758.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, Hoffmann E, Vlasuk GP, Jacobson EW. (2014) A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.. Br J Clin Pharmacol, 78 (1): (69-77). [PMID:24446723] |
| 2. Mercken EM, Mitchell SJ, Martin-Montalvo A, Minor RK, Almeida M, Gomes AP, Scheibye-Knudsen M, Palacios HH, Licata JJ, Zhang Y et al.. (2014) SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass.. Aging Cell, 13 (5): (787-96). [PMID:24931715] |
| 3. Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J et al.. (2015) A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.. PLoS ONE, 10 (11): (e0142081). [PMID:26556603] |
| 4. Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. (2016) Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.. Inflamm Bowel Dis, 22 (3): (607-14). [PMID:26595549] |
| 5. Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V et al.. (2014) Sirtuin 1 activator SRT2104 protects Huntington's disease mice.. Ann Clin Transl Neurol, 1 (12): (1047-52). [PMID:25574479] |